Sise ME, et al. - Researchers analyzed hepatitis C virus (HCV)-infected patients on direct-acting antiviral (DAA) therapy from 2013 to 2017 in this retrospective observational cohort study to compare the slopes of estimated glomerular filtration rate (eGFR) decline in the 3 years prior to DAA therapy to the slope post-therapy. They also compared albuminuria values before and after therapy. Overall 1,178 patients with a mean age of 56 were analyzed. Among participants, 64% were male, 71% were white, 21% were diabetic, and 42% had cirrhosis. According to the findings, chronic kidney disease (CKD) progression may be delayed by DAA therapy for HCVs infection. Having CKD at baseline and being non-diabetic were the identified predictors of eGFR improvement.